The risk of major adverse cardiac events (MACEs), MI, stroke, CHF, and coronary revascularization in RA patients treated with TCZ did not exceed that in patients treated with other biologics (TNF-α inhibitors, abatacept, and rituximab). The gene discussed is TNF; the disease is stroke disorder.